GeoVax Labs, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
39 Pages - GMD12087
$1,500.00

Summary

Global Markets Direct’s, ‘GeoVax Labs, Inc. - Product Pipeline Review - 2014’, provides an overview of the GeoVax Labs, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GeoVax Labs, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GeoVax Labs, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GeoVax Labs, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GeoVax Labs, Inc.’s pipeline products

Reasons to buy

- Evaluate GeoVax Labs, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GeoVax Labs, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GeoVax Labs, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GeoVax Labs, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GeoVax Labs, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GeoVax Labs, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
GeoVax Labs, Inc. Snapshot 5
GeoVax Labs, Inc. Overview 5
Key Information 5
Key Facts 5
GeoVax Labs, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
GeoVax Labs, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
GeoVax Labs, Inc. - Pipeline Products Glance 11
GeoVax Labs, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
GeoVax Labs, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
GeoVax Labs, Inc. - Drug Profiles 14
GOVX-B11 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
pGA2/JS7 DNA Vaccine + Recombinant Modified Vaccinia Ankara/HIV62B Vaccine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
GEO-D03 DNA vaccine + MVA/HIV62B (MVA62B) Vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
GOVXB-21 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
B–DNA-GM/MVA Therapeutic Vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
C–MVA 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DNA Clade C Vaccine + MVA Clade C Vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MVA Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GeoVax Labs, Inc. - Pipeline Analysis 28
GeoVax Labs, Inc. - Pipeline Products by Target 28
GeoVax Labs, Inc. - Pipeline Products by Route of Administration 29
GeoVax Labs, Inc. - Pipeline Products by Molecule Type 30
GeoVax Labs, Inc. - Recent Pipeline Updates 31
GeoVax Labs, Inc. - Dormant Projects 33
GeoVax Labs, Inc. - Company Statement 34
GeoVax Labs, Inc. - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
GeoVax Labs, Inc., Key Information 5
GeoVax Labs, Inc., Key Facts 5
GeoVax Labs, Inc. - Pipeline by Indication, 2014 7
GeoVax Labs, Inc. - Pipeline by Stage of Development, 2014 8
GeoVax Labs, Inc. - Monotherapy Products in Pipeline, 2014 9
GeoVax Labs, Inc. - Combination Treatment Modalities in Pipeline, 2014 10
GeoVax Labs, Inc. - Phase II, 2014 11
GeoVax Labs, Inc. - Phase I, 2014 12
GeoVax Labs, Inc. - Preclinical, 2014 13
GeoVax Labs, Inc. - Pipeline by Target, 2014 28
GeoVax Labs, Inc. - Pipeline by Route of Administration, 2014 29
GeoVax Labs, Inc. - Pipeline by Molecule Type, 2014 30
GeoVax Labs, Inc. - Recent Pipeline Updates, 2014 31
GeoVax Labs, Inc. - Dormant Developmental Projects,2014 33
GeoVax Labs, Inc., Subsidiaries 37

List of Figures
GeoVax Labs, Inc. - Pipeline by Top 10 Indication, 2014 7
GeoVax Labs, Inc. - Pipeline by Stage of Development, 2014 8
GeoVax Labs, Inc. - Monotherapy Products in Pipeline, 2014 9
GeoVax Labs, Inc. - Combination Treatment Modalities in Pipeline, 2014 10
GeoVax Labs, Inc. - Pipeline by Top 10 Target, 2014 28
GeoVax Labs, Inc. - Pipeline by Top 10 Route of Administration, 2014 29
GeoVax Labs, Inc. - Pipeline by Top 10 Molecule Type, 2014 30

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax